• PET Tracking of mRNA Antigen Expression: Limits

  2026-10-11

  A 2025 report describes a PET-based reporter strategy for measuring where and how long an mRNA-encoded antigen is expressed in vivo. The findings support non-invasive, whole-body tracking in female mice and male non-human primates, but they do not establish that reporter-fused antigen expression is equivalent to vaccine efficacy, nor do they provide evidence about any specific lipid excipient such as ALC-0159.

• Nonivamide Research: TRPV1, Inflammation and Cancer

  2026-10-10

  A source-grounded overview of Nonivamide as a Capsaicin analog, examining TRPV1 signaling, the 2025 neuroimmune study, reported cancer-related findings, evidence strength, and important translational limitations.

• Camptothecin, DNA Damage, and Adaptive Evolution

  2026-10-09

  A source-grounded overview of Camptothecin as a topoisomerase I inhibitor, its reported DNA-damage and cell-fate effects, and how these findings compare with new evidence on prion-regulated mutagenesis and drug resistance.

• Ibotenic Acid Toxicity in Mice: Dose and Time

  2026-10-09

  A 2026 study in Toxin Reviews provides a structured in vivo assessment of ibotenic acid toxicity in mice across dose and observation time. Its findings connect behavioral changes, transient biochemical disruption, early c-fos activation, and reduced Nissl bodies, while also showing why these markers should not be interpreted as direct evidence of human neurodegenerative disease.

• Amikacin Sulfate: From MIC to Granuloma

  2026-10-08

  Explore how Amikacin Sulfate acts as an aminoglycoside antibiotic and why granuloma-directed delivery could reshape research on non-tuberculous mycobacterial infections. This evidence-focused analysis separates established mechanism, mouse-model findings, and translational limitations.

• GDC-0941: Research Context and Evidence Boundaries

  2026-10-08

  A source-grounded overview of GDC-0941 as a PI3K inhibitor, covering its reported biochemical profile, conceptual oncology applications, evidence provenance, comparison with recent pancreatic cancer research, and limits on interpretation.

• Cinoxacin: From UTI Activity to Evidence Design

  2026-10-07

  Cinoxacin is a quinolone antibiotic with a historically defined Gram-negative activity profile. This article reframes its value for urinary tract infection research, bacterial prostatitis research, and antibiotic resistance studies through evidence design, pharmacology, and applicability limits.

• Difloxacin HCl: An Evidence-Bound Research Map

  2026-10-07

  Difloxacin HCl is a quinolone antimicrobial antibiotic with distinct research applications in bacterial DNA replication inhibition and multidrug resistance reversal. This evidence-bound guide separates established mechanisms from exploratory interpretation and uses mitotic checkpoint research to clarify how mechanistic claims should be evaluated.

• Acetoacetic Acid Sodium Salt: Evidence Guide

  2026-10-06

  Acetoacetic acid sodium salt, also called sodium 3-oxobutanoate, is a sodium-form ketone body metabolite used to frame questions in energy metabolism research. Vendor specifications establish chemical identity and handling information, while peer-reviewed ketone-body literature supports biological relevance but does not establish clinical efficacy for the product.

• Malate, Metabolic Flux, and Translational Immunology

  2026-10-06

  Malate is more than a TCA-cycle metabolite: it is a context-sensitive lens on mitochondrial redox, metabolic flux, and tumor–immune communication. This thought-leadership analysis connects malate biology with recent findings on PDHA1 succinylation and macrophage immune escape in cholangiocarcinoma while defining the evidence boundaries for translational research.

• Canagliflozin: Reading a Negative mTOR Result

  2026-10-05

  Canagliflozin hemihydrate is best understood through the distinction between SGLT2 biology and mTOR pathway screening. This article interprets a recent drug-sensitized yeast study, explains what its negative result does—and does not—demonstrate, and outlines evidence-aware applications in metabolic research.

• EGCG Nanoparticles Enhance FLASH Radiotherapy

  2026-10-05

  A 2026 study reports that functionalized, self-assembled epigallocatechin gallate nanoparticles, termed BENPs, can sensitize 4T1 tumor models to FLASH radiotherapy while promoting antitumor immune responses. The work connects enhanced radiation-associated oxidative and DNA damage with tumor control and immune remodeling, but its translational relevance remains limited by the preclinical model and the need for independent validation.

• Plk1 Control of p31comet in Checkpoint Disassembly

  2026-10-04

  Kaisari et al. identify Polo-like kinase 1 (Plk1) as a regulator that restrains p31comet-dependent disassembly of mitotic checkpoint complexes. Their evidence supports a phosphorylation-based mechanism at p31comet S102, helping explain how cells avoid premature checkpoint inactivation during mitosis while defining important boundaries for interpretation.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-10-03

  Kaisaria and colleagues identify Polo-like kinase 1 (Plk1) as a regulator that restrains p31comet-driven disassembly of mitotic checkpoint complexes through phosphorylation at serine 102. The findings provide a mechanistic explanation for how cells may prevent premature checkpoint termination while distinguishing this cell-cycle pathway from antimicrobial and drug-resistance applications of Difloxacin HCl.

• Minocycline HCl in iMSC-EV Assays

  2026-10-01

  Minocycline HCl can serve as a mechanistic perturbation tool when testing inflammatory signaling, microglial responses, and extracellular-vesicle bioactivity. This workflow combines formulation control, dose-response testing, and scalable iMSC-EV production to distinguish antimicrobial, anti-inflammatory, and cell-survival effects.

8641 records 3/577 page Previous Next 12345 下5页 Last page